Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0ZG3D
|
|||
Drug Name |
PMID29649907-Compound-30
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
SALK INSTITUTE FOR BIOLOGICAL STUDIE
|
|||
Structure |
Download2D MOL |
|||
Formula |
C32H32FN3O3
|
|||
Canonical SMILES |
CN1C2=C(C=C(C=C2)C3=CC(=C(C=C3)CN(C4=CC=CC(=C4)C=CC(=O)OC)C(=O)C5CCCCC5)F)C=N1
|
|||
InChI |
1S/C32H32FN3O3/c1-35-30-15-14-24(18-27(30)20-34-35)25-12-13-26(29(33)19-25)21-36(32(38)23-8-4-3-5-9-23)28-10-6-7-22(17-28)11-16-31(37)39-2/h6-7,10-20,23H,3-5,8-9,21H2,1-2H3/b16-11+/i21D
|
|||
InChIKey |
NOJHCAUXLPQOOD-STTMTRHISA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Farnesoid X-activated receptor (FXR) | Target Info | Agonist | [1] |
Target's Patent Info | Farnesoid X-activated receptor (FXR) | Target's Patent Info | [1] | |
KEGG Pathway | Bile secretion | |||
Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
Reactome | Recycling of bile acids and salts | |||
PPARA activates gene expression | ||||
Endogenous sterols | ||||
WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
Nuclear Receptors Meta-Pathway | ||||
Farnesoid X Receptor Pathway | ||||
Drug Induction of Bile Acid Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.